Skip to content

Determine if Apparent Diffusion Coefficient (ADC) Values Can Differentiate Tumors From Normal Tissue

Retrospective - Prospective - Study to Determine if Apparent Diffusion Coefficient (ADC) Values Can Differentiate Tumors From Normal Tissues at 3T MRI

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00723463
Enrollment
200
Registered
2008-07-28
Start date
2006-06-30
Completion date
2016-07-31
Last updated
2016-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Cancer, Neck Cancer

Brief summary

The purpose of this study is to determine normal measurements (ADC values) from the head and neck of healthy volunteers using 3T MRI.

Detailed description

The purpose of this study is to determine normal measurements (ADC values) from the head and necks of healthy subjects using 3T MRI.

Interventions

PROCEDURE3T MRI scan

Establishing/evaluating apparent diffusion coefficient (ADC) values using a 3T MRI scan to differentiate tumors from normal tissue.

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
University of Michigan
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Healthy subjects 18 years of age or older.

Exclusion criteria

* Under 18 years of age * Women of child bearing potential * Pregnant or lactating women * All potential volunteers will be pre-screened by MRI personnel to determine if there is any medical reason that you should not be included in this study.

Design outcomes

Primary

MeasureTime frame
To determine if ADC values determined at 3T are different between normal tissues and tumors arising from the extracranial head and neck.1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026